EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Structure–Activity Relationship of Antibody–Oligonucleotide Conjugates: Evaluating Bioconjugation Strategies for Antibody–siRNA Conjugates for Drug Development

Michael Cochran, Danny Arias, Rob Burke, David Chu, Gulin Erdogan, Michael Hood, Philip Kovach, Hae Won Kwon, Yanling Chen, Michael Moon, Christopher D Miller, Hanhua Huang und 2 weitere

Journal of Medicinal Chemistry · 12.09.2024 · 67 (17) · 14852-14867

DOI: 10.1021/acs.jmedchem.4c00802 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 28.08.2024. Verfasst von Michael Cochran und 13 weiteren Autor:innen. Beteiligte Einrichtung: Avidity Biosciences, Inc., 10578 Science Center Drive Suite 125. San Diego, California 92121, United States. Hauptthemen laut MEDLINE: RNA, Small Interfering, Immunoconjugates. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-oligonucleotide conjugates are a promising class of therapeutics for extrahepatic delivery of small interfering ribonucleic acids (siRNAs). These conjugates can be optimized for improved delivery and mRNA knockdown (KD) through understanding of structure-activity relationships. In this study, we systematically examined factors including antibody isotype, siRNA chemistry, linkers, conjugation chemistry, PEGylation, and drug-to-antibody ratios (DARs) for their impact on bioconjugation, pharmacokinetics (PK), siRNA delivery, and bioactivity. Conjugation site (cysteine, lysine, and Asn297 glycan) and DAR proved critical for optimal conjugate PK and siRNA delivery. SiRNA chemistry including 2' sugar modifications and positioning of phosphorothioates were found to be critical for delivery and duration of action. By utilizing cleavable and noncleavable linkers, we demonstrated the impact of linkers on PK and mRNA KD. To achieve optimal properties of antibody-siRNA conjugates, a careful selection of siRNA chemistry, DAR, conjugation sites, linkers, and antibody isotype is necessary.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, Small InterferingImmunoconjugatesStructure-Activity RelationshipHumansAnimalsDrug DevelopmentOligonucleotidesMiceRNA, Messenger

Substanzen

RNA, Small InterferingImmunoconjugatesOligonucleotidesRNA, Messenger

Autor:innen und Institutionen

  • Avidity Biosciences, Inc., 10578 Science Center Drive Suite 125. San Diego, California 92121, United States.

Zitieren

APA

Cochran, M., Arias, D., Burke, R., Chu, D., Erdogan, G., Hood, M., Kovach, P., Kwon, H. W., Chen, Y., Moon, M., Miller, C. D., Huang, H., Levin, A., & Doppalapudi, V. R. (2024). Structure–Activity Relationship of Antibody–Oligonucleotide Conjugates: Evaluating Bioconjugation Strategies for Antibody–siRNA Conjugates for Drug Development. Journal of Medicinal Chemistry, 67(17), 14852-14867. https://doi.org/10.1021/acs.jmedchem.4c00802

Vancouver

Cochran M, Arias D, Burke R, Chu D, Erdogan G, Hood M, et al. Structure–Activity Relationship of Antibody–Oligonucleotide Conjugates: Evaluating Bioconjugation Strategies for Antibody–siRNA Conjugates for Drug Development. Journal of Medicinal Chemistry. 2024;67(17):14852-14867. doi:10.1021/acs.jmedchem.4c00802

BibTeX
@article{Cochran2024,
  author = {Cochran, Michael and Arias, Danny and Burke, Rob and Chu, David and Erdogan, Gulin and Hood, Michael and Kovach, Philip and Kwon, Hae Won and Chen, Yanling and Moon, Michael and Miller, Christopher D and Huang, Hanhua and Levin, Arthur and Doppalapudi, Venkata Ramana},
  title = {Structure–Activity Relationship of Antibody–Oligonucleotide Conjugates: Evaluating Bioconjugation Strategies for Antibody–siRNA Conjugates for Drug Development},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  volume = {67},
  number = {17},
  pages = {14852--14867},
  doi = {10.1021/acs.jmedchem.4c00802}
}
Kostenlos starten →